Artificial Intelligence (AI) principles published in 1956 included the recommendation to use algorithms for solving complex processes. The creation of the Roussel Uclaf Causality Assessment Method (RUCAM) was published in 1993 with integration of an intelligent algorithm to solve issues of causality assessment in cases of complex suspected drug induced liver injury (DILI) cases. Other causality assessment methods (CAMs) published before the era of AI and RUCAM followed rather general principles without precise and valid algorithm.

Fluoropyrimidines compose the backbone of regimens to treat many common solid tumors, including gastrointestinal (GI), breast and head/neck. As we continue to use these agents routinely, recognition of rare but real toxicities, such as cardiotoxicity, has also improved. The treatment options for patients who have encountered fluoropyrimidine-induced cardiotoxicity are limited as many anti-angiogenic drugs also pose a cardiac risk.

Purpose: As long-acting reversible contraceptive choices are becoming more popular among young women, proper informed consent over potential complications should be addressed when such decisions are made. A local case series was analyzed to consider the risk of intrauterine device (IUD) fracture. Materials and Methods: A retrospective review of provider experience with the intrauterine device over a seven-year period was undertaken, to specifically analyze the incidence of IUD embedment and fracture in the studied population.

Cancer is the second most common cause of death worldwide, accounting for an estimated 9.6 million deaths in the year 2018, a number that is expected to grow to more than 13 million by 2030. In the past decade, we have witnessed unprecedented scientific advancement in the understanding of cancer etiology, prevention, diagnosis and development of new therapeutic strategies.

Pharmaceutical companies have been actively adopting artificial intelligence (AI) approaches for drug discovery and are starting to focus this technology on clinical trials. The shift from large-scale collaborations to smaller strategic partnerships and recently to internal teams has led to increased headcounts that are being organized to deliver AI across the enterprise. Although the urgency of the COVID-19 could have been a perfect test case for leveraging AI, it drew awareness to the obstacles of data access.